Summary
- Summary pending editorial review.
Key Facts
| Fact | Value |
|---|---|
| Drug Acquisition Cost | $4.9 billion |
| Disease Targeted | IgA nephropathy |
| Marker Reduction | 50% |
Strategic angle: Vertex reported that its drug, acquired for $4.9 billion, halved a key marker of IgA nephropathy in late-stage trials.
| Fact | Value |
|---|---|
| Drug Acquisition Cost | $4.9 billion |
| Disease Targeted | IgA nephropathy |
| Marker Reduction | 50% |